Related Experiment Video
Updated: Apr 17, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.4K
NUT midline carcinoma
1Department of Pathology, Brigham and Women's Hospital, harvard Medical School, 75 Francis Street, Boston, Massachusetts, 02115, USA. cfrench@partners.org
Nature Reviews. Cancer
|February 18, 2015
Summary
NUT midline carcinoma is a highly aggressive cancer lacking effective treatments. Researchers are investigating whether novel bromodomain and extra terminal (BET) inhibitors could offer a new therapeutic option for this rare disease.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- NUT midline carcinoma (a type of squamous cell carcinoma) is exceptionally aggressive.
- There is a critical unmet need for effective therapies for patients diagnosed with this rare cancer.
Purpose of the Study:
- To evaluate the potential of novel bromodomain and extra terminal (BET) inhibitors as a therapeutic strategy.
- To explore new treatment avenues for NUT midline carcinoma.
Main Methods:
- Investigational study of BET inhibitors.
- Analysis of therapeutic efficacy in preclinical models (details not provided in abstract).
Main Results:
- Results are pending or not detailed in the provided abstract.
- The study aims to determine if BET inhibitors show promise.
Conclusions:
- The potential of BET inhibitors for treating NUT midline carcinoma requires further investigation.
- This research seeks to address the urgent need for novel therapeutic interventions.
